Stocktoria
AstraZeneca PLC AZN.ST
AstraZeneca PLC (AZN.ST) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 0.17% (safety: moderate). FY2025 revenue was $58.7B at a 17.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | -0.017 |
| Retained earnings / assets | 0.096 |
| EBIT / assets | 0.117 |
| Equity / liabilities | 0.745 |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
FAQ
Is AZN.ST financially healthy?
AstraZeneca PLC's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does AZN.ST pay a dividend, and is it safe?
Yes. AstraZeneca PLC pays a dividend yielding about 0.17% with a 48.6% payout ratio, rated “moderate” for safety.
How profitable is AZN.ST?
In FY2025, AstraZeneca PLC had a net margin of 17.4% and a return on equity of 21.0%.
Is AZN.ST overvalued or undervalued?
AstraZeneca PLC trades at about 287.6× trailing earnings — below its 10-year norm (10-year range 252.2×–646.0×, median 365.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for AZN.ST?
The average Wall-Street price target for AstraZeneca PLC is $1,905.62, about 1.3% above the recent price, from 3 analysts.
Is AZN.ST a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AstraZeneca PLC: a Piotroski F-score of 8/9, an Altman Z″ in the grey zone, a P/E of about 285.3×, a dividend yield of 0.17%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · SE · as of 2025-12-31. Figures in USD. Facts plus Stocktoria's own computed scores — not investment advice.